immunotherapy is well documented, there is also an increased risk of sideeffects in bee-venom-treated patients and in those with rapid dose increase. Methods: This report describes the first case of a patient in the literature with Jessner's Lymphocytic infiltration as a side effect of venom immunotherapy. This is a chronic, benign, T cell pseudolymphoma characterized by the occurrence of recurrent, asymptomatic, smooth, erythematous, non-scaling papules or plaques. However, the exact cause of Jessner's Lymphocytic Infiltration is unknown. Results: The case here reported was a 61 year-old male pediatrician, who has been followed by at our Immunology Service because of an immediate allergy to a bee sting managed with venom immunotherapy. His chief complaint was an anaphylactic reaction after 5 minutes of a bee sting. The onset of his symptoms was gradual and began just 25 minutes after the sting. The venom immunotherapy regimen was planned and the protocol immediately began without premedication. But during the initial phases of treatment, on the third dose of immunotherapy, he reported severe itching. After complaining of itching, many erythematous papules and plaques on his chest were developed. The lesions flared up for 3 days period just after injection and decreased afterwards. The type of lesions and their location supported the diagnosis of Jessner disease, which had also a histopathological confirmation. Conclusions: We herein report this case to call attention to this side effect of VIT that there may be more similar cases never reported. Medical Pharmacology, Gulhane School of Medicine, Ankara, Turkey. Background: Chemical and mechanic iritations may play causative role in development of lichenoid reactions in oral mucosa, similar to skin, in predisposed patients. It has recently been reported that lichenoid reactions and Wickham striae with papular/reticular characteristics are observed in mucosal regions which are in direct contact with amalgam restorations (1). A 38-year-old male patient admitted initially to the Department of Oral Diagnosis and Radiology, chiefly complaining of bilateral buccal pain and itching. In his intraoral inspection, hyperkeratotic white lesions at his molar teeth level at both right and left buccal mucosa were observed. The purpose of this study is to find out the nature and decide on the management of these buccal lesions. Methods: In dental inspection of the patient, large amalgam restorations and white lesions in buccal surface in direct contact with amalgam were observed in left first and second, and right second molar teeth region. A 4-mm punch biopsy from buccal mucosa was performed. In addition, a skin patch test with amalgam was done in back region of the patient. Results: In punch biopsy, histopathological features were compatible with lichenoid mucositis. In addition, skin patch test results indicated a very strong positive reaction to amalgam. The lesion healed up after replacement of restorations with composite filling material. The patient, his family and his dental practitioner were strictly advised to use alternative restorative materials in case of a need for restoration. Conclusions: Amalgam and its components may cause type IV hypersensitivity reactions (1) and, very unusually, immediate hypersensitivity (2). The clinician should be aware of all possible pathological etiologies of white lesions. If there is any doubt about the diagnosis and management of an anusual oral lesion, referral to appropriate specialists is mandatory.
Medical Pharmacology, Gulhane School of Medicine, Ankara, Turkey. Background: Chemical and mechanic iritations may play causative role in development of lichenoid reactions in oral mucosa, similar to skin, in predisposed patients. It has recently been reported that lichenoid reactions and Wickham striae with papular/reticular characteristics are observed in mucosal regions which are in direct contact with amalgam restorations (1) . A 38-year-old male patient admitted initially to the Department of Oral Diagnosis and Radiology, chiefly complaining of bilateral buccal pain and itching. In his intraoral inspection, hyperkeratotic white lesions at his molar teeth level at both right and left buccal mucosa were observed. The purpose of this study is to find out the nature and decide on the management of these buccal lesions. Methods: In dental inspection of the patient, large amalgam restorations and white lesions in buccal surface in direct contact with amalgam were observed in left first and second, and right second molar teeth region. A 4-mm punch biopsy from buccal mucosa was performed. In addition, a skin patch test with amalgam was done in back region of the patient. Results: In punch biopsy, histopathological features were compatible with lichenoid mucositis. In addition, skin patch test results indicated a very strong positive reaction to amalgam. The lesion healed up after replacement of restorations with composite filling material. The patient, his family and his dental practitioner were strictly advised to use alternative restorative materials in case of a need for restoration. Conclusions: Amalgam and its components may cause type IV hypersensitivity reactions (1) and, very unusually, immediate hypersensitivity (2) . The clinician should be aware of all possible pathological etiologies of white lesions. If there is any doubt about the diagnosis and management of an anusual oral lesion, referral to appropriate specialists is mandatory.
Ioannis Sidiropoulos, MD, Athanasios Beltsis, MD, Elena Gigi, MD, Anna Sykla, MD, Aristea Bellou, MD, and Maria Raptopoulou-Gigi, MD. Allergy, Ippokration Hospital, Thessaloniki, Greece. Background: BA Interferon (IFN)-based therapy for chronic hepatitis C (CHC) is associated with adverse hypersensitivity reactions (HRs). However, data on HRs to IFN in every-day clinical practice are lacking. We conducted a retrospective study to identify the incidence, management and outcome of such reactions. Methods: A review of the electronic files of all CHC patients followed in our tertiary referral center from January 1990 to November 2010 was conducted to identify patients submitted to IFN-based treatment and HRs to such treatment. Results: During the study period, 832 CHC patients were identified, 545 (65.5%) of whom received IFN-based treatment. Overall, 221 (40.5%) patients received at least one treatment cycle with IFN-a 6 ribavirin (RBV), 170 (31.2%) patients received at least one treatment cycle with pegylated (PEG)-IFN a2a 1 RBV and 189 (34.7%) patients received at least one treatment cycle with PEG-IFN a2b 1 RBV. Fifty-five treatment cycles were complicated by HRs in 54 patients (female 20, median age 39 years, range 22-65 years). Presenting symptoms of HRs were: skin rash in 46 patients (pruritic in 20), generalized pruritus in 7 patients and aphthous mucosal ulcers in 2 patients. HRs occurred in 9 patients treated with IFN-a (4.1%), 23 patients treated with PEG-IFN a2a (13.5%) and 23 patients treated with PEG-IFN a2b (12.1%) (P ¼ 0.002). Management of HRs included no intervention in 18 (32.7%) cases, topical treatment in 10 (18.2%) cases, antihistamine administration in 15 (27.3%) cases, temporary cessation of treatment or dose reduction in 3 (5.5%) cases, switch from PEG-IFN to IFN-a in 4 (7.3%) cases and immediate termination of treatment in 5 (9.1%) cases. The outcome was complete remission of the HR in 33 (60%) cases, remission sufficient to allow continuation of treatment in 13 (23.6%) cases and treatment termination in 8 (14.5%) cases, while one (1.8%) patient was lost to follow-up after the HR. Overall, 2 (0.9%) patients discontinued IFN-a, 3 (1.8%) PEG-IFN a2a and 3 (1.6%) PEG-IFN a2b due to HRs (P ¼ 0.737). Conclusions: Hypersensitivity reactions to IFN-based and especially to PEG-IFN based treatment regimens are occasionally encountered in CHC patients and may rarely lead to treatment termination.
DRUG ALLERGY 2
387 Hypersensitivity Syndrome Associated with Phenytoin Sodium Elizabeth Mendieta. Mexico City, Mexico. Background: The drug-induced hypersensitivity syndrome (DIHS) is a systemic reaction for drug-induced idiosyncratic. We report 1 in 1000 to 1 in 10,000 exposures to aromatic anticonvulsant. In the case of phenytoin is estimated at 2.3 to 4.5 per 10,000 exposures. There is a deficit of microsomal epoxide hydroxylase causing accumulation of toxic metabolites. Occurs between 2 weeks to 3 months after drug exposure; it is characterized by maculopapular rash, erythema midface, fever, lymphadenopathy, with alteration of the hematologic system with eosinophilia, peripheral or atypical lymphocytosis. Described reactivation of herpes virus (HHV-6 and 7).
Comorbidities during the syndrome such as type 1 diabetes, encephalitis, and long-term sequelae such as thyroid dysfunction, systemic lupus erythematosus, etc. 1 Methods: We report a 39 year old female with history of traumatic brain injury (TBI) received proflaxis with phenytoin sodium 100 mg 1vo c/8 hours, 4 weeks after starting with fever, malaise, sore throat, cervical lymphadenopathy, appeared itchy rash in face, neck. Admitted with malaise, generalized rash, edema midface, cheilitis, jaundice, cervical lymphadenopathy, axillary and inguinal and hepatomegaly.We continued to study probable hypersensitivity syndrome asking paraclinical studies including blood count, liver function tests.We Background: Ten-to-twenty percent of hospitalized patients experience drug adverse reactions. There are few epidemiological data of drug hypersensitivity in inpatients in brazilian population. Our aim was to analyze the main clinical and epidemiological data of drug hypersensitivity reactions in hospitalized patients and to assess the importance of the allergist's evaluation. Methods: A prospective study was developed in an Allergy Clinic of a Service in São Paulo, Brazil, from January 2010 to January 2011. We evaluated the cases in which the allergist was assessed. The patients were studied based on history of hypersensitivity reactions to drugs (HRD) using an adapted ENDA (European Network of Drug Allergy) questionnaire. We analyzed clinical and epidemiological data of drug hypersensitivity reactions and assessed differences of the allergist evaluation. Results: Of all 80 cases in which the allergist was assessed, 65 (81%) were for HRD. The mean age was 57 years, 49 (75%) were women. Fifty (89%) experienced non-immediate reactions, 8 of them were severe adverse cutaneous reactions. Eight (12%) had just positive history of HRD, without reaction at the time of the evaluation. Neurosurgery (15), Infectious Diseases (11), Vascular surgery (8) were the main Clinics who assessed our specialty. Non-steroidal anti-inflammatory drugs (21), antiepileptics (16) and non-b-lactams antibiotics (15) were the most important pharmacological groups. Thirty (46%) patients were in use of more than 5 drugs at the time of the reaction, but in 46 (70%) evaluations there was 01 culprit drug suspected by the allergist. There was discordance between the allergist and the non-allergist opinion about the suspected drug in 13 (20%) cases. In 50% of cases other Clinics were assessed for the same reason. Eleven (17%) patients had history of HRD with the same pharmacological group before.
Conclusions: HRD is the main cause why the allergist is assessed. The pharmacological groups related to these HRD were different from the previously described. The history of HRD is still not appropriate asked from the non-allergists. The evaluation of the allergist can help to manage HRD properly. Thorax Disease Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. Background: Adverse reactions to local anesthetics (LA) are frequent and often referred to as allergic. Although immune-mediated reactions are rare, it should be investigated for suspected cases. The objective of this study was to determine the frequency of positive skin test to these drugs in patients with a suspected history of allergic reactions and describe the main sociodemographic characteristics of these individuals. Methods: Retrospective study of medical records of patients attended at Policlínica Geral do Rio de Janeiro Allergic Clinic, between 2008 and 2011. The parameters evaluated were the test indication and the patient ages and gender. The drug tested was that the patient had a history of suspicion. Patients underwent skin prick and intradermal tests and subcutaneous provocation. Descriptive statistical analysis of the data was performed. Results: It was performed 160 tests (125 female). Three of this total was excluded due to inconclusive results. In women, the highest proportion of tests was in the age group from 41 to 60 years (43%), while in males the higher concentration was at a youngest age group: 21 to 40 years (41%).The most common indication (103 cases, 65%) for the tests was a previous suspected anaphylactic reaction by LA. Seven of 157 tests had a positive result (4.4%), 6 of them occurred in women (4.8%). Only one test resulted in a type of anaphylactic reaction response (0.67%).All patients who presented positive response to the test had a history of per-anesthetic reaction that suggested an immune-mediated mechanism. Conclusions: In patients with a history of previous reaction to local anesthetics, the skin tests with these drugs have a key role in the prevention of anaphylaxis, and on guidance for adequate anesthetic procedures.
Protamine Allergy
Christine Hafner, MD, Background: An anaphylactic reaction to protamine sulfate during cardiac surgery is a rare but known entity. Preoperative prediction and outcome of such a reaction is still unclear. A 68-year-old man presented for elective coronary artery bypass grafts. His medical history included hypertension and he was non-diabetic. Review of his angiogram indicated 2-vessel coronary artery disease. According to the patient's notes, he had a known allergy to shellfish and avoids fish due to personal discomfort, although the exact nature of his reaction to fish was not well described. The information prompted the thoracic surgery team to alert the allergologist to perform an allergological checkup before thoracic surgery. Methods: Skin prick tests were performed with standard solutions for shrimp, fish-mix, mackerel and salmon (Bencard, Munich, Germany). Protamine sulfate (CP Pharmaceuticals Ltd, Wrexham, UK) was pricked undiluted and was tested intradermally diluted 1:10. Physiological saline and 0.01%
